
TransCode Therapeutics Inc. (NASDAQ:RNAZ) announced on Wednesday that it has entered a definitive agreement to acquire Polynoma LLC, a privately held biotechnology firm focused on immuno-oncology.
The acquisition adds Polynoma's lead candidate, seviprotimut-L, a novel polyvalent shed antigen vaccine being developed for the adjuvant treatment of stage IIB and IIC melanoma, to TransCode's development pipeline.